STOCK TITAN

Surmodics Inc - SRDX STOCK NEWS

Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

Surmodics Inc. (Ticker: SRDX) operates at the intersection of healthcare, life sciences, and medical technology, specializing in the development and commercialization of innovative products designed to improve the detection and treatment of diseases. Founded with a focus on cutting-edge coating technologies, the company has built a strong reputation as a trusted partner to leading and emerging medical device, diagnostic, and life sciences companies. Surmodics' proprietary coatings are engineered to enhance the performance of medical devices, enabling them to function more effectively in challenging clinical environments.

From Coating Technologies to Whole-Product Solutions

In recent years, Surmodics has undergone a transformative shift in its business model. Historically recognized for its expertise in providing advanced coating solutions, the company has expanded its capabilities to offer comprehensive, whole-product solutions. This strategic evolution was catalyzed by key acquisitions that bolstered its product development and manufacturing capabilities. By integrating its core technology expertise with end-to-end product development, Surmodics now delivers complete medical device solutions that address complex clinical challenges.

Core Business Segments

  • Medical Device Solutions: Surmodics develops and manufactures medical devices that incorporate its proprietary coating technologies. These solutions are designed to improve patient outcomes by enhancing device performance, reducing complications, and enabling minimally invasive treatments.
  • In Vitro Diagnostics (IVD): The company also provides critical components and technologies for diagnostic assays, including substrates and reagents that enable accurate and reliable disease detection. This segment underscores Surmodics' commitment to advancing healthcare through innovation in diagnostics.

Market Position and Competitive Landscape

Surmodics operates in a highly specialized niche within the broader medical technology and life sciences industry. Its expertise in coatings gives it a competitive edge, particularly in applications where device performance and biocompatibility are critical. By transitioning to whole-product solutions, the company positions itself as a more comprehensive partner to its clients, differentiating from competitors who may focus solely on either coatings or device manufacturing. This dual capability allows Surmodics to capture greater value across the product lifecycle, from initial development to commercialization.

Partnerships and Value Proposition

Surmodics partners with some of the world's leading medical device and life sciences companies, leveraging its technology to solve complex medical challenges. Its value proposition lies in its ability to combine deep technical expertise with innovative product development, enabling its partners to bring advanced medical solutions to market more efficiently. By focusing on collaboration and innovation, Surmodics plays a pivotal role in improving patient care and advancing medical science.

Challenges and Opportunities

While Surmodics' transformation into a whole-product solutions provider opens new revenue streams, it also presents challenges such as increased operational complexity, regulatory compliance, and the need for sustained R&D investment. However, the company's established reputation in coatings and diagnostics provides a strong foundation to navigate these challenges. Its focus on addressing unmet medical needs positions it well to capitalize on growing demand for advanced medical technologies.

Conclusion

Surmodics Inc. exemplifies innovation and adaptability in the medical technology sector. By evolving from a coatings specialist to a provider of comprehensive medical device solutions, the company has strengthened its market position and expanded its impact on healthcare. Its commitment to improving the detection and treatment of diseases underscores its significance as a key enabler of medical advancements, making it an important player in the life sciences and medical device industries.

Rhea-AI Summary
Surmodics, Inc. will present 24-month data from the SWING Trial, evaluating the Sundance™ Sirolimus Drug-Coated Balloon's safety and performance in treating occlusive lesions in the infra-popliteal arteries. The trial reports an 8.3% major adverse event rate at 6 months and an 80% target lesion primary patency rate at 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. (NASDAQ:SRDX) announced that 36-month data from its TRANSCEND clinical trial will be presented at the 50th Annual VEITH Symposium. Dr. Peter A. Schneider will share the trial's safety and efficacy data in a session focused on randomized controlled trial updates on drug coated balloons and drug eluting stents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Surmodics, Inc. has launched Preside hydrophilic coatings, its most advanced medical device coating technology. The coatings offer low-friction and low-particulate generation, improving distal access for neurovascular applications and crossing for challenging coronary lesions. The coatings are formulated to balance enhanced lubricity and coating durability. Surmodics has secured the first 510(k) device clearance for this technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Summary
Surmodics, Inc. to release Q4 2023 financial results on November 8
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
-
Rhea-AI Summary
Surmodics, Inc. (SRDX) reported a total revenue of $52.5 million, a 111% increase year-over-year, with a GAAP Diluted EPS of $0.52. The company obtained FDA premarket approval for the SurVeil DCB, leading to a $27 million milestone payment, and received FDA 510(k) clearance for its Pounce LP Thrombectomy System. Medical Device revenue grew by 163%, while In Vitro Diagnostics revenue decreased by 12%. Surmodics now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the prior year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.11%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags

FAQ

What is the current stock price of Surmodics (SRDX)?

The current stock price of Surmodics (SRDX) is $29.367 as of March 6, 2025.

What is the market cap of Surmodics (SRDX)?

The market cap of Surmodics (SRDX) is approximately 549.5M.

What does Surmodics Inc. do?

Surmodics Inc. specializes in medical devices and diagnostics, providing advanced coating technologies and whole-product solutions to improve disease detection and treatment.

How does Surmodics generate revenue?

Surmodics generates revenue through partnerships with medical device and life sciences companies, offering both coating technologies and comprehensive medical device solutions.

What industries does Surmodics serve?

Surmodics serves the healthcare, life sciences, and medical technology industries, focusing on medical devices and in vitro diagnostics.

What is unique about Surmodics' business model?

Surmodics combines its expertise in coating technologies with whole-product development, enabling it to offer end-to-end solutions that address complex medical challenges.

Who are Surmodics' key customers?

Surmodics partners with leading and emerging medical device, diagnostic, and life sciences companies, providing solutions to enhance their products' performance and effectiveness.

What challenges does Surmodics face in its market?

Challenges include regulatory compliance, operational complexities from its transformation, and competition from larger players in the medical device and diagnostics sectors.

How does Surmodics differentiate from competitors?

Surmodics differentiates by offering both advanced coating technologies and comprehensive medical device solutions, providing a unique combination of expertise and end-to-end capabilities.

What role does innovation play in Surmodics' strategy?

Innovation is central to Surmodics' strategy, enabling the company to develop advanced technologies and products that address unmet medical needs and improve patient outcomes.
Surmodics Inc

Nasdaq:SRDX

SRDX Rankings

SRDX Stock Data

549.47M
13.74M
3.39%
85.25%
3.24%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE